Literature DB >> 9525646

Infection of human B lymphocytes with lymphocryptoviruses related to Epstein-Barr virus.

A Moghaddam1, J Koch, B Annis, F Wang.   

Abstract

Lymphocryptoviruses (LCVs) naturally infecting Old World nonhuman primates are closely related to the human LCV, Epstein-Barr virus (EBV), and share similar genome organization and sequences, biologic properties, epidemiology, and pathogenesis. LCVs can efficiently immortalize B lymphocytes from the autologous species, but the ability of a given LCV to immortalize B cells from other Old World primate species is variable. We found that LCV from rhesus monkeys did not immortalize human B cells, and EBV did not immortalize rhesus monkey B cells. In this study, baboon LCV could not immortalize human peripheral blood B cells but could readily immortalize rhesus monkey B cells. Thus, efficient LCV-induced B-cell immortalization across distant Old World primate species appears to be restricted by a species-specific block. To further characterize this species restriction, we first cloned the rhesus monkey LCV major membrane glycoprotein and discovered that the binding epitope for the EBV receptor, CD21, was highly conserved. Stable infections of human B cells with recombinant amplicons packaged in rhesus monkey or baboon LCV envelopes were also consistent with a species-restricted block occurring after virus binding and penetration. Transient infections of human B cells with simian LCV resulted in latent LCV EBNA-2 gene expression and activation of cell CD23 gene expression. EBV-immortalized human B cells could be coinfected with baboon LCV, and the simian virus persisted and replicated in human B cells. Thus, several lines of evidence indicate that the species restriction for efficient LCV-induced B-cell immortalization occurs beyond virus binding and penetration. This has important implications for the study of LCV infection in Old World primate models and for human xenotransplantation where simian LCVs may be inadvertently introduced into humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525646      PMCID: PMC109784     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Identification of a naturally occurring recombinant Epstein-Barr virus isolate from New Guinea that encodes both type 1 and type 2 nuclear antigen sequences.

Authors:  J M Burrows; R Khanna; T B Sculley; M P Alpers; D J Moss; S R Burrows
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

2.  Squamous epithelial proliferative lesions associated with rhesus Epstein-Barr virus in simian immunodeficiency virus-infected rhesus monkeys.

Authors:  G B Baskin; E D Roberts; D Kuebler; L N Martin; B Blauw; J Heeney; C Zurcher
Journal:  J Infect Dis       Date:  1995-08       Impact factor: 5.226

3.  Isolation of intertypic recombinants of Epstein-Barr virus from T-cell-immunocompromised individuals.

Authors:  Q Y Yao; R J Tierney; D Croom-Carter; G M Cooper; C J Ellis; M Rowe; A B Rickinson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

4.  Expression of Epstein-Barr-virus-related nuclear antigens and B-cell markers in lymphomas of SIV-immunosuppressed monkeys.

Authors:  S L Li; H Feichtinger; E Kaaya; P Migliorini; P Putkonen; G Biberfeld; J M Middeldorp; P Biberfeld; I Ernberg
Journal:  Int J Cancer       Date:  1993-10-21       Impact factor: 7.396

5.  Tap-1 and Tap-2 gene therapy selectively restores conformationally dependent HLA Class I expression in type I diabetic cells.

Authors:  F Wang; X Li; B Annis; D L Faustman
Journal:  Hum Gene Ther       Date:  1995-08       Impact factor: 5.695

6.  Contribution of conserved amino acids in mediating the interaction between EBNA2 and CBF1/RBPJk.

Authors:  P D Ling; S D Hayward
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

7.  Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx.

Authors:  C Alfieri; J Tanner; L Carpentier; C Perpête; A Savoie; K Paradis; G Delage; J Joncas
Journal:  Blood       Date:  1996-01-15       Impact factor: 22.113

8.  Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.

Authors:  D A Scudiero; R H Shoemaker; K D Paull; A Monks; S Tierney; T H Nofziger; M J Currens; D Seniff; M R Boyd
Journal:  Cancer Res       Date:  1988-09-01       Impact factor: 12.701

9.  5' Coding and regulatory region sequence divergence with conserved function of the Epstein-Barr virus LMP2A homolog in herpesvirus papio.

Authors:  M Franken; B Annis; A N Ali; F Wang
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

10.  A monkey model for Epstein Barr virus-associated lymphomagenesis in human acquired immunodeficiency syndrome.

Authors:  H Feichtinger; S L Li; E Kaaya; P Putkonen; K Grünewald; K Weyrer; D Böttiger; I Ernberg; A Linde; G Biberfeld
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

View more
  27 in total

1.  Structural, functional, and genetic comparisons of Epstein-Barr virus nuclear antigen 3A, 3B, and 3C homologues encoded by the rhesus lymphocryptovirus.

Authors:  H Jiang; Y G Cho; F Wang
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Evidence of an oncogenic gammaherpesvirus in domestic dogs.

Authors:  Shih-Hung Huang; Philip J Kozak; Jessica Kim; Georges Habineza-Ndikuyeze; Charles Meade; Anita Gaurnier-Hausser; Reema Patel; Erle Robertson; Nicola J Mason
Journal:  Virology       Date:  2012-03-08       Impact factor: 3.616

3.  Mapping regions of Epstein-Barr virus (EBV) glycoprotein B (gB) important for fusion function with gH/gL.

Authors:  Aileen E Plate; Jessica J Reimer; Theodore S Jardetzky; Richard Longnecker
Journal:  Virology       Date:  2011-03-03       Impact factor: 3.616

4.  Host Range Restriction of Epstein-Barr Virus and Related Lymphocryptoviruses.

Authors:  Janine Mühe; Fred Wang
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

5.  Antibodies to lytic infection proteins in lymphocryptovirus-infected rhesus macaques: a model for humoral immune responses to epstein-barr virus infection.

Authors:  Nina Orlova; Mark H Fogg; Angela Carville; Fred Wang
Journal:  Clin Vaccine Immunol       Date:  2011-07-06

6.  Comprehensive analysis of Rhesus lymphocryptovirus microRNA expression.

Authors:  Kasandra J-L Riley; Gabrielle S Rabinowitz; Joan A Steitz
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

7.  Functional homology of gHs and gLs from EBV-related gamma-herpesviruses for EBV-induced membrane fusion.

Authors:  Jasmina Omerović; Richard Longnecker
Journal:  Virology       Date:  2007-05-02       Impact factor: 3.616

8.  Mechanisms that regulate Epstein-Barr virus EBNA-1 gene transcription during restricted latency are conserved among lymphocryptoviruses of Old World primates.

Authors:  I K Ruf; A Moghaddam; F Wang; J Sample
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

9.  Transcriptional activation signals found in the Epstein-Barr virus (EBV) latency C promoter are conserved in the latency C promoter sequences from baboon and Rhesus monkey EBV-like lymphocryptoviruses (cercopithicine herpesviruses 12 and 15).

Authors:  E M Fuentes-Pananá; S Swaminathan; P D Ling
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

10.  Functional analysis of glycoprotein L (gL) from rhesus lymphocryptovirus in Epstein-Barr virus-mediated cell fusion indicates a direct role of gL in gB-induced membrane fusion.

Authors:  Aileen E Plate; Jasmina Smajlović; Theodore S Jardetzky; Richard Longnecker
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.